- Home
- FLYE vs AYTU Comparison
FLYE vs AYTU Comparison
Compare FLYE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- AYTU
- Stock Information
- Founded
- FLYE 2018
- AYTU N/A
- Country
- FLYE United States
- AYTU United States
- Employees
- FLYE N/A
- AYTU N/A
- Industry
- FLYE Aerospace
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- AYTU Health Care
- Exchange
- FLYE Nasdaq
- AYTU Nasdaq
- Market Cap
- FLYE 15.5M
- AYTU 15.0M
- IPO Year
- FLYE 2024
- AYTU N/A
- Fundamental
- Price
- FLYE $0.58
- AYTU $2.36
- Analyst Decision
- FLYE
- AYTU
- Analyst Count
- FLYE 0
- AYTU 0
- Target Price
- FLYE N/A
- AYTU N/A
- AVG Volume (30 Days)
- FLYE 147.4K
- AYTU 29.8K
- Earning Date
- FLYE 11-10-2024
- AYTU 11-12-2024
- Dividend Yield
- FLYE N/A
- AYTU N/A
- EPS Growth
- FLYE 1.84
- AYTU N/A
- EPS
- FLYE 0.06
- AYTU N/A
- Revenue
- FLYE $32,236,745.00
- AYTU $81,002,000.00
- Revenue This Year
- FLYE N/A
- AYTU N/A
- Revenue Next Year
- FLYE N/A
- AYTU N/A
- P/E Ratio
- FLYE $10.01
- AYTU N/A
- Revenue Growth
- FLYE 36.51
- AYTU N/A
- 52 Week Low
- FLYE $0.51
- AYTU $2.20
- 52 Week High
- FLYE $7.62
- AYTU $3.50
- Technical
- Relative Strength Index (RSI)
- FLYE N/A
- AYTU 44.84
- Support Level
- FLYE N/A
- AYTU $2.26
- Resistance Level
- FLYE N/A
- AYTU $2.47
- Average True Range (ATR)
- FLYE 0.00
- AYTU 0.15
- MACD
- FLYE 0.00
- AYTU -0.01
- Stochastic Oscillator
- FLYE 0.00
- AYTU 16.10
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.